YISAIPU® ( An etanercept biosimilar) ( DrugBank: Etanercept, Yisaipu )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05424393 (ClinicalTrials.gov) | March 4, 2022 | 15/6/2022 | Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients | Long-term Real-world Prospectiv Observational Study on Maintenance Treatment With YISAIPU, an Etanercept Biosimilar, for Patients Wih Rheumatoid Arthritis of Fujian Province of China | Rheumatoid Arthritis | Drug: YISAIPU® ( An etanercept biosimilar);Drug: csDMARDs | The First Affiliated Hospital of Xiamen University | NULL | Recruiting | 18 Years | 75 Years | All | 500 | China |